Abivax SA
PAR:ABVX
Abivax SA
Total Receivables
Abivax SA
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Abivax SA
PAR:ABVX
|
Total Receivables
€17m
|
CAGR 3-Years
16%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Total Receivables
€20.1m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Total Receivables
€43.7m
|
CAGR 3-Years
56%
|
CAGR 5-Years
37%
|
CAGR 10-Years
18%
|
|
|
Inventiva SA
PAR:IVA
|
Total Receivables
€47.8m
|
CAGR 3-Years
40%
|
CAGR 5-Years
48%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Total Receivables
$15.7m
|
CAGR 3-Years
13%
|
CAGR 5-Years
24%
|
CAGR 10-Years
6%
|
|
|
Sensorion SA
PAR:ALSEN
|
Total Receivables
€9.1m
|
CAGR 3-Years
15%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
|
Abivax SA
Glance View
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
See Also
What is Abivax SA's Total Receivables?
Total Receivables
17m
EUR
Based on the financial report for Jun 30, 2025, Abivax SA's Total Receivables amounts to 17m EUR.
What is Abivax SA's Total Receivables growth rate?
Total Receivables CAGR 5Y
32%
Over the last year, the Total Receivables growth was -3%. The average annual Total Receivables growth rates for Abivax SA have been 16% over the past three years , 32% over the past five years .
